

## Original Investigation

# Effect of CPAP on Blood Pressure in Patients With Obstructive Sleep Apnea and Resistant Hypertension

## The HIPARCO Randomized Clinical Trial

Miguel-Angel Martínez-García, MD, PhD; Francisco Capote, MD, PhD; Francisco Campos-Rodríguez, MD, PhD; Patricia Lloberes, MD, PhD; María Josefa Díaz de Atauri, MD, PhD; María Somoza, MD, PhD; Juan F. Masa, MD, PhD; Mónica González, MD, PhD; Lirios Sacristán, MD; Ferrán Barbé, MD, PhD; Joaquín Durán-Cantolla, MD, PhD; Felipe Aizpuru, PhD; Eva Mañas, MD, PhD; Bienvenido Barreiro, MD, PhD; Mar Mosteiro, MD, PhD; Juan J. Cebrián, MD, PhD; Mónica de la Peña, MD, PhD; Francisco García-Río, MD, PhD; Andrés Maimó, MD, PhD; Jordi Zapater, MD; Concepción Hernández, MD, PhD; Nuria Grau SanMarti, MD, PhD; Josep María Montserrat, MD, PhD; for the Spanish Sleep Network

**IMPORTANCE** More than 70% of patients with resistant hypertension have obstructive sleep apnea (OSA). However, there is little evidence about the effect of continuous positive airway pressure (CPAP) treatment on blood pressure in patients with resistant hypertension.

**OBJECTIVE** To assess the effect of CPAP treatment on blood pressure values and nocturnal blood pressure patterns in patients with resistant hypertension and OSA.

**DESIGN, SETTING, AND PARTICIPANTS** Open-label, randomized, multicenter clinical trial of parallel groups with blinded end point design conducted in 24 teaching hospitals in Spain involving 194 patients with resistant hypertension and an apnea-hypopnea index (AHI) of 15 or higher. Data were collected from June 2009 to October 2011.

**INTERVENTIONS** CPAP or no therapy while maintaining usual blood pressure control medication.

**MAIN OUTCOMES AND MEASURES** The primary end point was the change in 24-hour mean blood pressure after 12 weeks. Secondary end points included changes in other blood pressure values and changes in nocturnal blood pressure patterns. Both intention-to-treat (ITT) and per-protocol analyses were performed.

**RESULTS** A total of 194 patients were randomly assigned to receive CPAP ( $n = 98$ ) or no CPAP (control;  $n = 96$ ). The mean AHI was 40.4 (SD, 18.9) and an average of 3.8 antihypertensive drugs were taken per patient. Baseline 24-hour mean blood pressure was 103.4 mm Hg; systolic blood pressure (SBP), 144.2 mm Hg; and diastolic blood pressure (DBP), 83 mm Hg. At baseline, 25.8% of patients displayed a dipper pattern (a decrease of at least 10% in the average nighttime blood pressure compared with the average daytime blood pressure). The percentage of patients using CPAP for 4 or more hours per day was 72.4%. When the changes in blood pressure over the study period were compared between groups by ITT, the CPAP group achieved a greater decrease in 24-hour mean blood pressure (3.1 mm Hg [95% CI, 0.6 to 5.6];  $P = .02$ ) and 24-hour DBP (3.2 mm Hg [95% CI, 1.0 to 5.4];  $P = .005$ ), but not in 24-hour SBP (3.1 mm Hg [95% CI, -0.6 to 6.7];  $P = .10$ ) compared with the control group. Moreover, the percentage of patients displaying a nocturnal blood pressure dipper pattern at the 12-week follow-up was greater in the CPAP group than in the control group (35.9% vs 21.6%; adjusted odds ratio [OR], 2.4 [95% CI, 1.2 to 5.1];  $P = .02$ ). There was a significant positive correlation between hours of CPAP use and the decrease in 24-hour mean blood pressure ( $r = 0.29$ ,  $P = .006$ ), SBP ( $r = 0.25$ ;  $P = .02$ ), and DBP ( $r = 0.30$ ,  $P = .005$ ).

**CONCLUSIONS AND RELEVANCE** Among patients with OSA and resistant hypertension, CPAP treatment for 12 weeks compared with control resulted in a decrease in 24-hour mean and diastolic blood pressure and an improvement in the nocturnal blood pressure pattern. Further research is warranted to assess longer-term health outcomes.

**TRIAL REGISTRATION** clinicaltrials.gov Identifier: NCT00616265

JAMA. 2013;310(22):2407-2415. doi:10.1001/jama.2013.281250

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Miguel-Ángel Martínez-García, MD, PhD, Servicio de Neumología, Hospital Universitario y Politécnico La Fe, Valencia, Bulevar Sur s/n, 46026-Valencia, Spain (mianmartinezgarcia@gmail.com).

Systemic hypertension is one of the most treatable cardiovascular risk factors.<sup>1</sup> Between 12% and 27% of all hypertensive patients require at least 3 antihypertensive drugs for adequate blood pressure control and are considered patients with resistant hypertension.<sup>2-4</sup> Patients with resistant hypertension are almost 50% more likely to experience a cardiovascular event than hypertensive patients without resistant hypertension, and the incidence of resistant hypertension is expected to increase.<sup>5</sup>

Obstructive sleep apnea (OSA) affects 4% to 6% of the general middle-aged population<sup>6,7</sup> and increases with age.<sup>8</sup> It is characterized by the repeated collapse of the upper airway during the night, causing intermittent hypoxemia and sleep disruption, which in turn are associated with an increased risk for neurocognitive and cardiovascular morbidities.<sup>9</sup> Recent studies have shown that OSA may contribute to poor control of blood pressure<sup>10</sup> and that a very high percentage (>70%) of resistant hypertension patients have OSA.<sup>11</sup> Accordingly, international guidelines now recognize OSA as one of the most common risk factors of resistant hypertension.<sup>4</sup>

Continuous positive airway pressure (CPAP) is the treatment of choice for severe or symptomatic OSA.<sup>12</sup> A meta-analysis suggests that CPAP treatment reduces blood pressure levels to a clinically meaningful degree,<sup>13</sup> but whether this positive effect is more pronounced in patients with resistant hypertension is unclear because studies on this issue are scarce and based on single-center approaches.<sup>14-16</sup> The objective of our study was to conduct a randomized, multicenter clinical trial to assess the effect of CPAP treatment on blood pressure values and nocturnal blood pressure patterns of patients with resistant hypertension and OSA.

## Methods

### Study Design

This study was approved by the ethics committee of each participating center. All the participants provided informed signed consent to participate in the study. Our study was an open-label, randomized, multicenter clinical trial of parallel groups with a blinded end point design conducted in 24 teaching hospitals in Spain in patients diagnosed with resistant hypertension and OSA. Patients were randomly assigned to either CPAP or no therapy (control) and maintained their usual, unmodified blood pressure control medication.

### Selection of Patients

Patients were consecutively recruited from the Hypertension Clinical Units of the participating centers. Patients were initially eligible for participation in the study if they had primary resistant hypertension, were aged 18 to 75 years, and signed the informed consent to participate. All the major

causes of resistant hypertension were ruled out in each Hypertension Clinical Unit including primary aldosteronism, renal artery stenosis, and renal insufficiency. Initial exclusion criteria also included pregnancy, disabling hypersomnia requiring urgent treatment (defined as an Epworth Sleepiness Scale [ESS]  $\geq 18$ ), current use of CPAP treatment, poor adherence with antihypertensive treatment, long-term treatment with oral corticosteroids or nonsteroidal anti-inflammatory drugs, renal insufficiency (creatinine concentration higher than 1.5 mg/dL [to convert to micromoles per liter, multiply by 88.4] in peripheral blood sample), a cardiovascular event in the month prior to the inclusion in the study, and the regular use of sedative drugs such as benzodiazepines, major opiates, and antipsychotics, which could significantly modify the results of sleep studies and alcohol intake (more than 100 grams of alcohol per day).

## Procedures

### Initial Visit

At the initial visit, all the patients completed a standardized protocol that included general and anthropometric data, history of cardiovascular diseases, current medications, and clinical history related to OSA. The ESS was used to quantify daytime somnolence. Good adherence to the antihypertensive treatment was verified by means of the Haynes-Sackett test.<sup>17</sup> This test is a method for assessing self-reported adherence. Patients were also asked to bring the empty blister packs of their antihypertensive pills to check the number of tablets missed per month. Good adherence was considered to occur when the percentage of doses taken was between 80% and 120% of the prescribed dose (some patients took more than the prescribed dose).

### Sleep Studies

All the included patients underwent attended respiratory polygraphy<sup>18</sup> in the sleep laboratory of each center. Respiratory polygraphy included continuous recording of oronasal flow and pressure, heart rate, thoracic and abdominal respiratory movements, and oxygen saturation (SaO<sub>2</sub>). Polygraphy data were scored manually by trained personnel. Apnea was defined as an interruption of oronasal airflow for more than 10 seconds. Hypopnea was defined as a 30% to 90% reduction in oronasal airflow for more than 10 seconds, associated with an oxygen desaturation of 4% or higher. Apnea-hypopnea index (AHI) was defined as the number of apneas plus hypopneas per hour of recording, and TSat<sub>90</sub> was defined as the percentage of recording time with SaO<sub>2</sub> less than 90%. Those tests in which the patients claimed to sleep less than 4 hours or in which there were less than 5 hours of nocturnal recording were repeated. Central sleep apnea was defined as at least 50% of respiratory events having a pattern of apnea or hypopnea without respiratory effort.

### 24-Hour Ambulatory Blood Pressure Monitoring

All patients with an AHI of 15 or higher underwent an initial 24-hour ABPM measurement to ascertain the presence of resistant hypertension and its control in accordance with standard recommendations.<sup>19,20</sup>

The summary values in the ABPM report of each patient in the data analysis were used. Data related to the average daytime and nighttime systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (defined as  $[\frac{2}{3} \text{ DBP value}] + [\frac{1}{3} \text{ SBP value}]$ )<sup>21</sup>; types of nocturnal blood pressure patterns (according to the increase [riser], decrease [dipper], or absence of a difference [nondipper] of at least 10% in the value of the average nighttime blood pressure levels compared to the average daytime levels);<sup>20</sup> variability of blood pressure (defined as the standard deviation of the 24-hour mean blood pressure); heart rate; and both SBP and DBP 24-hour peak and valley values (defined as the maximum [peak] and minimum [valley] 24-hour blood pressure values) were recorded. Blood pressure levels were measured every 20 minutes in both the daytime and nighttime periods.

The sleeping and awaking periods were determined by instructing the patients to record the approximate times when they fell asleep and woke up. The 24-hour ABPM criteria used to define resistant hypertension were blood pressure that remained above goal (ie, average SBP  $\geq 130$  mm Hg, average DBP  $\geq 80$  mm Hg, or both) in spite of concurrent use of at least 3 antihypertensive medication agents prescribed at doses that provide optimal benefit—1 of them being, ideally, a diuretic, if no contraindication exists.<sup>4</sup> Patients not fulfilling resistant hypertension criteria were excluded from the study.

#### Main Outcome Measures

The primary end point was the change in the 24-hour ambulatory mean blood pressure from baseline to 12 weeks of CPAP or control. Secondary end points included changes in other blood pressure values, especially diurnal and nocturnal SBP and DBP, and changes in nocturnal blood pressure patterns.

#### Random Allocation

Patients with an AHI of 15 or higher in whom resistant hypertension was confirmed were eligible for randomization. The clinician responsible used a specific software designed for this study (Random function of JavaScript math package) to determine the group allocation for patients. Random allocation stratified by site was used without any other restriction. The software only revealed the allocation group when an investigator provided the data of a fully eligible patient, which guaranteed the concealment of the randomization sequence.

#### CPAP Pressure Titration

For those patients randomized to CPAP treatment, optimal CPAP pressure was titrated in the sleep laboratory on a second night by an auto CPAP device (REMstar Pro M Series with C-Flex, Philips Respironics) within a period of less than 15 days after the diagnostic study to obtain a fixed CPAP pressure value, according to a previous validation by the Spanish Sleep Network.<sup>22</sup> The optimal pressure was determined by 2 blinded expert researchers, based on the visual evaluation of the raw data recording from the night study, with no significant leaks (less than 0.40 L/s). This fixed pressure was then maintained throughout the study in those patients assigned to the CPAP group.

#### Follow-up


Treatment with CPAP was continued for 3 months, during which the patient had direct contact with the research team at all times for clinical problem-solving issues. Medical appointments were scheduled for all patients (with or without CPAP) 2 weeks after randomization and, subsequently, at 4, 8, and 12 weeks. We considered adherence as adequate if the mean CPAP use was at least 4 hours per night. Every medical appointment involved protocol-based assessments of the following: adherence to CPAP and antihypertensive treatment, appearance of any noteworthy new medical circumstances (especially changes in treatments, clinical or anthropometric variables, or new vascular events), and reevaluation of the exclusion criteria. At the last medical appointment, after 12 weeks of treatment, a repeat 24-hour ABPM test was conducted in all patients. The CPAP device used was able to store all the data from the 3 months of use and record the residual AHI, leaks, and other information for each night for analysis using specific software (Encore Pro, Philips Respironics). Data were collected from June 2009 to October 2011.

#### Statistical Analysis

Continuous variables were expressed as mean (SD), while categorical variables were reported as absolute numbers and percentages. The normality of the distribution of variables was tested using the Kolmogorov-Smirnov test. Calculation of the sample size aimed to detect a reduction of 4 mm Hg or more in 24-hour mean blood pressure, assuming a pooled standard deviation of 8.7,<sup>23</sup> an  $\alpha$  error of 5%, and a statistical power of 80%, with a total of 70 patients needed per randomized treatment group, including both an intention-to-treat (ITT) analysis (analyzed data from all randomized patients) and a per-protocol analysis (analyzed data only from patients with adequate adherence to CPAP who finished the study).

The intragroup differences from the beginning to the end of the study were evaluated with a paired *t* test. Intergroup comparisons of the change in blood pressure were assessed by analysis of covariance (ANCOVA) to adjust for baseline blood pressure values. The hospital of inclusion and all the clinically relevant cardiovascular risk factors that differed significantly at baseline were also included as covariates. The validity of the models was assessed by the coefficient of determination  $R^2$ . Also, graphical examination was performed in order to confirm the assumptions of linearity and normality of the residuals. The  $\chi^2$  test was used to compare dichotomous variables. Multiple imputation techniques were used to estimate values for those patients without valid measurements of blood pressure after the 12-week follow-up. The multiple imputation method is implemented under the assumption that the missing data are missing at random. For the 20 patients with missing follow-up blood pressure measurements, imputed values of these measurements were generated on the basis of baseline blood pressure values, sex, age, AHI, ESS, and number of initial antihypertensive drugs. This was generated using multiple imputation by chained equations, the *ice* command in Stata (StataCorp), version 11.

Figure 1. Flowchart of the Study



ABPM indicates ambulatory blood pressure monitor; AHI, apnea-hypopnea index; and CPAP, continuous positive airway pressure.

Logistic regression analysis was used to estimate the odds ratio (OR) of having a dipper or riser pattern in the CPAP group compared with the control group. Baseline status was included as a covariate. Appropriate 95% CIs were also calculated. A 2-sided *P* value less than .05 was considered significant. Data management and statistical analyses were performed using Stata, version 11, and SPSS predictive analytics software (IBM), version 21.

## Results

Of the initial 266 recruited patients, 194 were randomized, 98 to the CPAP group and 96 to the control group (ITT population), and 174 (87 CPAP, 87 control) of these completed the study and had valid 24-hour ABPM measurements (Figure 1). Of the 194 randomized patients, 133 patients (68.6%) were men. The mean (SD) for age was 56.0 (9.5) years; body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), 34.1 (5.4); AHI, 40.4 (18.9) events per hour (96.1% of events were obstructive); and antihypertensive drugs taken per patient, 3.8 (0.9). Patients showing an AHI of 30 or higher were 63.9%; an ESS of 10 or higher, 43.2%. The mean ESS was 9.1 (SD, 3.7; range, 1-18). No patient had central sleep apnea. The mean (SD) for baseline 24-hour mean blood pressure was 103.4 (9.6) mm Hg; SBP, 144.2 (12.5) mm Hg; and DBP, 83.0 (10.5) mm Hg. Patients with a nondipper blood pressure nocturnal pattern were 42.8%; riser, 31.4% (Table 1). Ten patients were not taking a diuretic as antihypertensive treatment because of adverse effects. The use of antihypertensive medication

is detailed in Table 2. Patients who did not complete the follow-up were similar to those who completed it, except that they took slightly more antihypertensive medication at baseline (4.3 incomplete study vs 3.7 completed study; *P* = .02).

The average use of CPAP treatment was 5 (1.9) hours per night, with 71 patients (72.4%) using it at least 4 hours per night. The mean CPAP pressure used was 8.5 (2.1) mm Hg. The residual AHI following the application of CPAP during the titration study was 4.1 (3.8) mm Hg.

### Intention-to-Treat Analysis

For the ITT analysis, imputed values for blood pressure measurements were calculated for the 20 patients with missing follow-up blood pressure measurements due to failure to complete the protocol or an invalid 24-hour ABPM study. When the changes in blood pressure during the study period were compared between study groups by ITT (98 patients in the CPAP group; control group, 96 patients), the CPAP group achieved a greater decrease in 24-hour mean blood pressure (3.1 mm Hg [95% CI, 0.6 to 5.6]; *P* = .02) and 24-hour DBP (3.2 mm Hg [95% CI, 1.0 to 5.4]; *P* = .005), but not 24-hour SBP (3.1 mm Hg [95% CI, -0.6 to 6.7]; *P* = .10) compared to the control group (Table 3). The differences appeared greater for nocturnal blood pressure than for daytime blood pressure, although the 95% CIs for changes in nocturnal and daytime blood pressure overlapped. The model did not change when it was adjusted for potential confounders (baseline blood pressure, AHI, ESS, nocturnal blood pressure pattern, and previous cardiovascular events) except for the statistically significant reduction observed in SBP values not seen in the unadjusted model (Table 3). Regarding nocturnal patterns, the percentage of patients displaying a nocturnal blood pressure dipper pattern at the 12-week follow-up was greater in the CPAP group than in the control group (35.9% CPAP vs 21.6% control; adjusted OR, 2.4 [95% CI, 1.2 to 5.1]; *P* = .02). (Table 4). Also, fewer patients in the CPAP group displayed a nocturnal riser pattern at the end of the study compared to the control group (adjusted OR, 0.45 [95% CI, 0.23 to 0.91]; *P* = .03) (Table 4).

There were no differences in the percentage of patients reaching a normotensive range in the ABPM (<130/80 mm Hg) between the CPAP group and control group at the end of the study (18.4% CPAP vs 13.8% control; *P* = .41).

### Analysis According to CPAP Tolerance (Per-Protocol Analysis)

In a per-protocol analysis (71 patients in the CPAP group; control group, 87 patients), patients in the CPAP group showed a statistically significant decrease in 24-hour mean blood pressure of 4.4 mm Hg (95% CI, 1.8-7), *P* = .001; SBP, 4.9 mm Hg (95% CI, 1.2-8.6), *P* = .01; and DBP, 4.1 mm Hg (95% CI, 1.9-6.4), *P* < .001. This difference was more evident during the night, with a decrease of 7.1 mm Hg (*P* = .003) in nocturnal SBP and 4.1 mm Hg (*P* = .003) in nocturnal DBP. Moreover, the proportion of patients who had a dipper pattern at the end of follow-up was greater in the CPAP group

Table 1. Baseline Characteristics of All Randomized Patients

	Mean (SD)		
	All Patients	Control Group	CPAP Group
Patients, No.	194	96	98
Age, y	56.0 (9.5)	58.2 (9.6)	57.8 (9.5)
Men, No. (%)	133 (68.6)	62 (64.6)	71 (72.4)
BMI	34.1 (5.4)	33.6 (6.9)	34.3 (5.7)
≥30, No. (%)	113 (79.6)	52 (76.4)	61 (82.4)
Neck circumference, cm	42.2 (4.9)	41.5 (4.7)	42.9 (5.1)
Epworth Sleepiness Scale	9.1 (3.7)	9.3 (4.0)	8.9 (4.0)
≥10, No. (%)	76 (43.2)	43 (47.3)	33 (38.9)
Years since diagnosis of resistant hypertension	12.8 (8.6)	13.1 (8.0)	12.5 (9.2)
No. of systemic hypertension drugs	3.8 (0.9)	3.9 (0.9)	3.7 (0.9)
Past cardiovascular events, No. (%)	42 (21.4)	24 (25)	18 (18)
Apnea-hypopnea index, event/h	40.4 (18.9)	39.5 (19.2)	41.3 (18.7)
≥30, No. (%)	124 (63.9)	56 (58.3)	68 (69.4)
TSat <sub>90</sub> , median (IQR)	9 (2-20)	8 (2-19)	9.5 (4-22)
Mean O <sub>2</sub> saturation, %	92.0 (3.8)	92.0 (4.8)	91.9 (2.5)
24-h mean blood pressure, mm Hg	103.4 (9.6)	102.9 (9.6)	103.9 (9.6)
24-h SBP, mm Hg	144.2 (12.5)	143.5 (13.2)	144.9 (11.7)
Diurnal	146.1 (12.7)	145.1 (13.3)	147.2 (12.1)
Nocturnal	140.8 (16.3)	140.4 (16.8)	141.2 (15.8)
24-h DBP, mm Hg	83.0 (10.5)	82.6 (10.0)	83.4 (11.1)
Diurnal	85.2 (11.0)	84.6 (10.4)	85.7 (11.6)
Nocturnal	78.6 (11.7)	78.6 (11.1)	78.5 (12.4)
Nocturnal blood pressure pattern, No. (%)			
Dipper	50 (25.8)	25 (26.0)	25 (25.5)
Nondipper	83 (42.8)	37 (38.5)	46 (46.9)
Riser	61 (31.4)	34 (35.4)	27 (27.6)
Variability, mm Hg	11.7 (3.1)	11.6 (3.5)	11.7 (3.6)
Heart rate, beats/min	71.8 (11.3)	73.3 (11.1)	70.3 (11.7)
Valley blood pressure, mm Hg			
24-h SBP	111.5 (14.7)	111.0 (14.3)	111.9 (15.4)
24-h DBP	64.2 (12.2)	60.3 (11)	59.6 (11.6)
Peak blood pressure, mm Hg			
24-h SBP	160.9 (17.7)	160.2 (17.3)	161.8 (18)
24-h DBP	93.5 (13.1)	92.8 (12.4)	93.9 (13.7)

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure; TSat<sub>90</sub>, nighttime spent with an oxygen saturation below 90%.

(OR, 2.8 [95% CI, 1.3-6.3];  $P = .01$ ). Also, fewer patients in the CPAP group displayed a nocturnal riser pattern at the end of the study compared to the control group (OR, 0.43 [95% CI, 0.20-0.91];  $P = .03$ ).

Figure 2 shows a positive linear correlation between the number of hours of CPAP use and the decrease in 24-hour mean blood pressure ( $r = 0.29$ ,  $P = .006$ ); SBP, ( $r = 0.25$ ;  $P = .02$ ); and DBP, ( $r = 0.30$ ,  $P = .005$ ). Linear regression analysis shows an improvement of blood pressure figures of 1.3 mm Hg (95% CI, 0.4 to 2.2) for mean blood pressure; SBP, 1.9 mm Hg (95% CI, 0.6 to 3.3); and DBP, 1.0 mm Hg (95% CI, 0.1 to 1.8) for each additional hour of CPAP use.

## Discussion

There is clinical evidence that OSA is a risk factor for the development and poor control of systemic hypertension.<sup>10,24,25</sup> Nevertheless, great variability has been observed with respect to the effect of treatment with CPAP on blood pressure, probably on account of the multifactorial nature of systemic hypertension.<sup>5-22,24-29</sup> This has led to an increasing interest in the analysis of subgroups of patients who could potentially benefit from the CPAP treatment. Obstructive sleep apnea is highly prevalent in patients with resistant hypertension, regardless of

**Table 2. Use of Prescribed Antihypertensive Medication in Randomized Patients**

	No. (%)		
	All Patients	Treatment	
		Control Group	CPAP Group
Patients, No.	194	96	98
Diuretic <sup>a</sup>	184 (94.8)	89 (93.7)	95 (96.9)
Calcium channel blockers	142 (72.4)	69 (71.9)	73 (73)
Angiotensin II receptor blockers	132 (67.3)	64 (66.7)	68 (68)
β-Blockers	112 (57.1)	54 (56.3)	58 (58)
Angiotensin-converting enzyme inhibitor	75 (38.3)	38 (39.6)	37 (37)
α <sub>1</sub> -Blockers	65 (33.1)	32 (33.3)	33 (33)
Renin blockers	21 (10.7)	8 (8.3)	13 (13)
Others	8 (4.1)	4 (4.2)	4 (4)

Abbreviation: CPAP, continuous positive airway pressure.

<sup>a</sup> Ten patients were not taking diuretic treatment due to adverse effects.

**Table 3. Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure Levels in the Intention-to-Treat Population**

	Mean (SD)				Intergroup Crude <sup>a</sup> Differences (95% CI)	P Value	Intergroup Adjusted <sup>b</sup> Differences (95% CI)	P Value
	CPAP Group (n = 98)		Control Group (n = 96)					
	Baseline	Follow-up	Baseline	Follow-up				
BP variables, mm Hg <sup>c</sup>								
24-h mean BP	103.9 (9.6)	99.8 (14.6)	102.9 (9.6)	102.1 (18.2)	3.1 (0.6 to 5.6)	.02	3.9 (1.3 to 6.6)	.004
24-h SBP	144.9 (11.7)	140.2 (13.1)	143.5 (13.2)	142.3 (17.1)	3.1 (-0.6 to 6.7)	.10	4.2 (0.4 to 8.0)	.03
Diurnal	147.2 (12.1)	144.0 (13.7)	145.1 (13.3)	142.5 (16.2)	-0.3 (-4.0 to 3.5)	.89	1.1 (-2.9 to 5.2)	.59
Nocturnal	141.2 (15.8)	134.6 (16.4)	140.4 (16.8)	137.8 (19.4)	3.7 (-0.8 to 8.2)	.11	5.8 (1.1 to 10.5)	.02
24-h DBP	83.4 (11.1)	79.5 (11.5)	82.6 (10.0)	82.1 (12.7)	3.2 (1.0 to 5.4)	.005	3.8 (1.4 to 6.1)	.002
Diurnal	85.7 (11.6)	82.7 (12.5)	84.6 (10.4)	83.2 (13.2)	1.5 (-0.8 to 3.9)	.20	2.3 (-0.1 to 4.8)	.07
Nocturnal	78.5 (12.4)	75.4 (11.7)	78.6 (11.1)	77.5 (13.5)	2.1 (-0.6 to 4.7)	.13	3.3 (0.5 to 6.1)	.02
Valley BP								
24-h SBP	111.9 (15.4)	106.2 (17.8)	111.0 (14.3)	103.3 (20.2)	-2.6 (-7.9 to 2.6)	.32	-0.4 (-6.0 to 5.3)	.90
24-h DBP	59.6 (11.6)	57.4 (11.1)	60.3 (11.0)	58.4 (13.1)	0.5 (-2.3 to 3.3)	.71	2.2 (-0.7 to 5.1)	.14
Peak BP								
24-h SBP	161.8 (18.0)	150.5 (25.1)	160.2 (17.3)	149.6 (28.9)	-0.3 (-8.0 to 7.4)	.93	0.5 (-7.5 to 8.6)	.89
24-h DBP	93.9 (13.7)	88.4 (14.2)	92.8 (12.4)	92.8 (14.0)	5.0 (1.8 to 8.3)	.003	5.7 (2.3 to 9.2)	.001
BMI	34.3 (5.7)	34.5 (5.2)	33.6 (6.9)	33.6 (6.0)	-0.4 (-1.8 to 1.0)	.54	0.1 (-0.4 to 0.7)	.64
ESS	8.9 (4.0)	5.5 (4.1)	9.3 (4.0)	9.0 (4.5)	3.3 (2.3 to 4.2)	<.001	3.4 (2.4 to 4.3)	<.001
Heart rate, beats/min	70.3 (11.7)	70.1 (14.8)	73.3 (11.1)	73.0 (11.7)	0.9 (-2.3 to 4.0)	.59	0.6 (-2.8 to 3.9)	.74
Variability	11.7 (3.6)	11.9 (4.4)	11.6 (3.5)	12.6 (4.3)	0.8 (-0.5 to 2.0)	.24	0.4 (-0.8 to 1.6)	.52

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; ESS, Epworth Sleepiness Scale; SBP, systolic blood pressure.

<sup>a</sup> Adjusted by baseline BP values.

<sup>b</sup> Adjusted by baseline BP, AHI, ESS, dipper or riser status, and previous cardiovascular events.

<sup>c</sup> Crude differences calculated as (change in CPAP group) - (change in control group).

other confounding variables such as the presence of obesity,<sup>11,30,31</sup> thus suggesting this subgroup of hypertensive patients is a potential worthwhile population for CPAP treatment.

International guidelines have pointed out that even minimal reductions in the blood pressure levels (to the order of 2-3 mm Hg of SBP) could have a clinically significant effect by greatly reducing subsequent cardiovascular mortality (between 6%-8% for stroke and 4%-5% for coronary heart disease).<sup>32</sup> Very few studies have assessed the role for CPAP treatment in patients with resistant hypertension and OSA. The available studies have found

clinically significant reductions in blood pressure levels, especially during the night and particularly in patients with good adherence to CPAP treatment. However, all of these studies had significant methodological limitations (eg, lack of randomization<sup>14,15</sup> and small cohorts)<sup>14-16</sup> leading their authors to emphasize the need for further studies with rigorous study designs. In line with the published evidence, our results confirm that there is a clinically and statistically significant reduction in both 24-hour mean and diastolic blood pressure levels, especially during the night and in those patients with acceptable CPAP adherence.

Table 4. Effect of Continuous Positive Airway Pressure Treatment on Prevalence of Blood Pressure Patterns


	No. (%)				OR (95% CI) <sup>a</sup>	P Value
	CPAP Group (n = 98)		Control Group (n = 96)			
	Baseline	Follow-up	Baseline	Follow-up		
Prevalence dipper pattern	25 (25.5)	35 (35.9)	25 (26.0)	21 (21.6)	2.4 (1.2-5.1)	.02
Prevalence riser pattern	27 (27.6)	20 (20.5)	34 (35.4)	35 (36.8)	0.45 (0.23-0.91)	.03

Abbreviations: CPAP, continuous positive airway pressure; OR, odds ratio.

<sup>a</sup> Adjusted for baseline status. Control group data were reference values. Odds

ratio (95% CI) of dipper or riser pattern 12 weeks after CPAP treatment relative to the control group.

Figure 2. Correlation Between Changes in 24-Hour Mean, Systolic, and Diastolic Blood Pressure and Number of Hours of Continuous Positive Airway Pressure Use



Correlation between continuous positive airway pressure (CPAP) use and change in blood pressure in the patients of the CPAP group who finished the follow-up.

The recovery of the dipper nocturnal pattern with antihypertensive treatment may be advantageous because the presence of nondipper or riser blood pressure nocturnal patterns has emerged as an independent cardiovascular risk factor. In our study, more than 70% of patients had a nondipper or riser pattern and CPAP treatment normalized the blood pressure nocturnal pattern in a significant percentage of these patients. Moreover, CPAP provided protection against having a riser pattern at the end of the study compared to the control group. This is an important point because patients with a riser blood pressure pattern exhibit the highest cardiovascular risk.<sup>33,34</sup>

Some authors have reported that the effect of CPAP treatment on blood pressure levels depends on the number of hours of CPAP use.<sup>28</sup> Our study corroborates this finding, with a significant correlation between the hours of CPAP use (especially in patients with at least 4 hours of use per night) and the decrease in blood pressure levels. Adherence to CPAP treatment was good in the present study, with more than 70% of patients using CPAP for 4 or more hours per night, an adherence rate similar to that reported in other large studies of patients with OSA.<sup>35</sup>

In our study we chose not to use sham CPAP as a placebo because studies have shown that excessive air leaking and low air pressure (necessary to deliver a very low, noneffective pressure of 2-3 cm H<sub>2</sub>O), along with the persistence of symptoms such as snoring or breathing pauses, makes the patients realize that they are not receiving an effective treatment.<sup>23,36</sup> Several studies have reported lower CPAP compliance with sham CPAP compared to optimal CPAP, suggesting that this device fails to function as a true placebo.<sup>37,38</sup>

The major strength of our study is its randomized multicenter clinical trial design with a sample size sufficient to enable both an ITT and per-protocol analyses. In addition, resistant hypertension was established by means of 24-hour ABPM, as recently recommended to provide more accurate estimates of blood pressure in these patients.<sup>19</sup> Nevertheless, this study has several limitations. First, respiratory polygraphy does not permit any quantification of the duration of sleep. This is unlikely to affect our conclusions because patients in our study had an average AHI of more than 40 events per hour (severe OSA). Indeed, the correlation between the AHI calculated from respiratory polygraphy and the AHI derived from full polysomnography is very high in severe OSA.<sup>39</sup> Second, in this trial, we opted for titration of a fixed pressure by means of an auto CPAP device and then used this target pressure for the 3 months of the study. This approach was used because fixed CPAP pressure is the most common method applied to OSA patients in Spain. Moreover, a recent study failed to demonstrate any differences in blood pressure levels when using fixed CPAP pressure in comparison to auto CPAP devices.<sup>40</sup>

## Conclusions

Among patients with OSA and resistant hypertension, CPAP treatment for 12 weeks, compared to control, resulted in a decrease in 24-hour mean and diastolic blood pressure and an improvement in the nocturnal blood pressure pattern. Further research is warranted to assess longer-term health outcomes.

## ARTICLE INFORMATION

**Author Affiliations:** Respiratory Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain (Martínez-García); Respiratory Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain (Capote); Respiratory Department, Hospital Universitario Valme, Sevilla, Spain (Campos-Rodríguez); Respiratory Department, Hospital Universitario Vall Hebrón, Barcelona, Spain (Lloberes); Respiratory Department, Hospital Universitario 12 de Octubre, Madrid, Spain (Díaz de Azañón); Respiratory Department, Consorcio Sanitario de Terrassa, Barcelona, Spain (Somoza); Respiratory Department, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain (Masa); Respiratory Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain (González); Respiratory Department, Hospital de Villajoyosa, Alicante, Spain (Sacristán); Institut de Recerca Biomèdica, IRB Lleida, Spain (Barbé); Bio-Araba Research Institute, Vitoria, Spain (Durán-Cantolla, Aizpuru); Clinical Research Unit, Hospital Universitario Araba, Vitoria, Spain (Durán-Cantolla, Aizpuru); Respiratory Department, Hospital Universitario Ramón y Cajal, Madrid, Spain (Mañás); Respiratory Department, Hospital Universitario Mutua de Terrassa, Barcelona, Spain (Barreiro); Respiratory Department, Hospital Universitario Xeral, Vigo, Spain (Mosteiro); Respiratory Department, Hospital Costa del Sol, Málaga, Spain (Cebrián); Respiratory Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain (de la Peña); Respiratory Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain (García-Río); Respiratory Department, Hospital Son Llatzer, Palma de Mallorca, Spain (Maimó); Respiratory Department, Hospital de Igualada, Barcelona, Spain (Zapater); Respiratory Department, Hospital Universitario de Las Palmas, Gran Canaria, Spain (Hernández); Respiratory Department, Hospital del Mar, Barcelona, Spain (Grau SanMartí); Respiratory Department, Hospital Clinic-IDIBAPS, Barcelona, Spain (Montserrat).

**Author Contributions:** Drs Martínez-García and Aizpuru had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Martínez-García, Lloberes, Somoza, Masa, Barbé, Cebrián, de la Peña, García-Río.

**Acquisition of data:** Martínez-García, Capote, Campos-Rodríguez, Lloberes, Díaz de Azañón, Somoza, Masa, González, Sacristán, Barbé, Durán-Cantolla, Mañás, Barreiro, Mosteiro, Cebrián, de la Peña, García-Río, Maimó, Zapater, Hernández, Grau, Montserrat.

**Analysis and interpretation of data:** Martínez-García, Capote, Campos-Rodríguez, Lloberes, Masa, Barbé, Durán-Cantolla, Aizpuru, Montserrat.

**Drafting of the manuscript:** Martínez-García, Capote, Campos-Rodríguez, Lloberes, Masa, Barbé, Durán-Cantolla, Aizpuru, Montserrat.

**Critical revision of the manuscript for important intellectual content:** Martínez-García, Capote, Campos-Rodríguez, Lloberes, Díaz de Azañón, Somoza, Masa, González, Sacristán, Barbé, Durán-Cantolla, Aizpuru, Mañás, Barreiro, Mosteiro, Cebrián, de la Peña, García-Río, Maimó, Zapater, Grau, Montserrat.

**Statistical analysis:** Aizpuru.

**Obtained funding:** Capote, Barbé, Zapater, Hernández, Montserrat.

**Administrative, technical, or material support:** Martínez-García, Capote, Campos-Rodríguez, Lloberes, Masa, Barbé, Montserrat.

**Study supervision:** Martínez-García, Capote, Campos-Rodríguez, Lloberes, Díaz de Azañón, Somoza, Masa, González, Sacristán, Barbé, Durán-Cantolla, Mañás, Barreiro, Mosteiro, Cebrián, de la Peña, García-Río, Maimó, Zapater, Hernández, Grau, Montserrat.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

**Funding/Support:** The study received a grant from Philips-Respironics, Sociedad Española de Neumología, Instituto de Salud Carlos III, and Sociedad Valenciana de Neumología.

**Role of the Sponsor:** The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**CIBER de Enfermedades Respiratorias (CIBERES) Investigators:** Miguel-Angel Martínez-García, MD, PhD, Patricia Lloberes, MD, PhD, María Josefa Díaz de Azañón, MD, PhD, Juan F. Masa, MD, PhD, Ferrán Barbé, MD, PhD, Joaquín Durán-Cantolla, MD, PhD, Francisco García-Río, MD, PhD, Josep María Montserrat, MD, PhD.

**Group Information:** The Spanish Sleep Network members are Juan Jose Soler, MD, PhD, and Pablo Catalán, MD (Hospital de Requena, Valencia); Irene Valero, MD, and María José Selma, MD (Hospital Universitario y Politécnico La Fe, Valencia); Antonio Grilo-Reina, MD (Hospital Valme, Sevilla); Carmen Carmona, MD, Ángeles Sánchez Armengol, MD, and Pedro Mañás Escorza, MD (Hospital Virgen del Rocío, Sevilla); Gabriel Sampol, MD, PhD (Hospital Vall Hebrón, Barcelona); Trinidad Diaz Cambriles, MD (Hospital 12 de Octubre, Madrid); Carles Sanjuán, MD, PhD, and MA FÉlez, MD (Hospital del Mar, Barcelona); Cristina Embid, MD (Hospital Clinic-IDIBAPS, Barcelona); Jaime Corral, MD, PhD, and Estefanía García-Ledesma, MD (Hospital San Pedro de Alcántara, Cáceres); María Pilar Cuellar, MD (Hospital de Marbella, Málaga); Javier Pierola, PhD (Hospital Son Espases, Palma de Mallorca); MJ Muñoz Martínez, MD (Hospital Universitario Xeral de Vigo); Manuel de la Torre, PhD, Gerard Torres, MD, and Silvia Gómez, MD (Institut de Recerca Biomèdica, IRB Lleida); Alberto Torre, MD; Raúl Gaera, MD, and David Romero, MD (Hospital Universitario La Paz, Madrid); Juan Bauzá Derouledé, MD (Hospital Son Llatzer, Palma de Mallorca); Rosa Esteban, MD, PhD (Hospital Universitario Ramón y Cajal, Madrid); Rosa Gómez, MD, PhD (Hospital Gregorio Marañón, Madrid); María Ángeles Martínez, MD, and Olga Cantalejo, MD (Hospital Marqués de Valdecilla, Santander); Vicenc Esteve, MD (Consorcio Sanitario de Terrassa); Ramón Caracho, MD, Cristina Martínez-Null, PhD, Carlos Egea, MD, PhD, and Laura Cancelo, MD (Hospital Universitario Araba, Vitoria); Amaia Latorre Ramos, MD, and Erika Miranda Serrano, MD (Unidad Investigación Osakidetza, Araba). All members are from Spain.

**Previous Presentation:** The results of the present study were presented in the annual Congress of the European Respiratory Society in Vienna (2012) as a thematic poster and in the annual congress of American Thoracic Society in Philadelphia (2013).

## REFERENCES

- Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. *J Hypertens*. 2007;25(9):1751-1762.
- Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. *Hypertension*. 2011;57(6):1076-1080.
- de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. *Hypertension*. 2011;57(5):898-902.
- Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension*. 2008;51(6):1403-1419.
- Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation*. 2012;125(13):1635-1642.
- Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 years. *Am J Respir Crit Care Med*. 2001;163(3 pt 1):685-689.
- Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*. 1993;328(17):1230-1235.
- Pavlova MK, Duffy JF, Shea SA. Polysomnographic respiratory abnormalities in asymptomatic individuals. *Sleep*. 2008;31(2):241-248.
- Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. *Proc Am Thorac Soc*. 2008;5(2):144-153.
- Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med*. 2000;342(19):1378-1384.
- Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. *J Hypertens*. 2001;19(12):2271-2277. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list\\_uids=11204288&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11204288&dopt=Abstract)
- Sanders MH, Montserrat JM, Farré R, Givelber RJ. Positive pressure therapy: a perspective on evidence-based outcomes and methods of application. *Proc Am Thorac Soc*. 2008;5(2):161-172.
- Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. *Hypertension*. 2007;50(2):417-423.
- Martínez-García MA, Gómez-Aldaravi R, Soler-Cataluña JJ, Martínez TG, Bernácer-Alpera B, Román-Sánchez P. Positive effect of CPAP



treatment on the control of difficult-to-treat hypertension. *Eur Respir J*. 2007;29(5):951-957.

15. Logan AG, Tkacova R, Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. *Eur Respir J*. 2003;21(2):241-247.
16. Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. *J Hypertens*. 2010;28(10):2161-2168.
17. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. *Lancet*. 1976;1(7972):1265-1268.
18. Masa JF, Corral J, Pereira R, et al. Effectiveness of home respiratory polygraphy for the diagnosis of sleep apnoea and hypopnoea syndrome. *Thorax*. 2011;66(7):567-573.
19. Pickering TG, Hall JE, Appel LJ, et al; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals. *Hypertension*. 2005;45(1):142-161.
20. Head GA, McGrath BP, Mihailidou AS, et al. Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. *J Hypertens*. 2012;30(2):253-266.
21. Franklin SS, Gustin W IV, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure: The Framingham Heart Study. *Circulation*. 1997;96(1):308-315.
22. Masa JF, Jimenez A, Durán J, et al. Alternative methods of titrating continuous positive airway pressure: a large multicenter study. *Am J Respir Crit Care Med*. 2004;170(11):1218-1224.
23. Hein H. Is sham CPAP a true placebo? *Am J Respir Crit Care Med*. 2002;165(2):305.
24. Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent risk factor for

uncontrolled hypertension. *J Hypertens*. 2000;18(6):679-685.

25. Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J, et al. Effect of continuous positive airway pressure on ambulatory blood pressure in patients with sleep apnea and hypertension: a placebo-controlled trial. *Chest*. 2006;129(6):1459-1467.
26. Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. *Lung*. 2007;185(2):67-72.
27. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. *Arch Intern Med*. 2007;167(8):757-764.
28. Montesi SB, Edwards BA, Malhotra A, Bakker JP. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. *J Clin Sleep Med*. 2012;8(5):587-596.
29. Durán-Cantolla J, Aizpuru F, Montserrat JM, et al; Spanish Sleep and Breathing Group. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. *BMJ*. 2010;341:c5991.
30. Martínez-García MA, Gómez-Aldaraví R, Gil-Martínez T, Soler-Cataluña JJ, Bernácer-Alpera B, Román-Sánchez P. Sleep-disordered breathing in patients with difficult-to-control hypertension. *Arch Bronconeumol*. 2006;42(1):14-20.
31. Lloberes P, Lozano L, Sampol G, et al. Obstructive sleep apnoea and 24-hour blood pressure in patients with resistant hypertension. *J Sleep Res*. 2010;19(4):597-602.
32. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure;

National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560-2572.

33. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. *Hypertension*. 2007;49(6):1235-1241.
34. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. *Hypertension*. 1994;24(6):793-801.
35. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. *Proc Am Thorac Soc*. 2008;5(2):173-178.
36. Schwartz SW, Cimino CR, Anderson WM. CPAP or placebo-effect? *Sleep*. 2012;35(12):1585-1586.
37. Hui DS, To KW, Ko FW, et al. Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness. *Thorax*. 2006;61(12):1083-1090.
38. Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. *Eur Respir J*. 2006;27(6):1229-1235.
39. Gugger M. Comparison of ResMed AutoSet (version 3.03) with polysomnography in the diagnosis of the sleep apnoea/hypopnoea syndrome. *Eur Respir J*. 1997;10(3):587-591.
40. Marrone O, Salvaggio A, Bue AL, et al. Blood pressure changes after automatic and fixed CPAP in obstructive sleep apnea: relationship with nocturnal sympathetic activity. *Clin Exp Hypertens*. 2011;33(6):373-380.